illionaire investor Bill Ackman’s argument for increasing his bet on besieged drugmaker Valeant Pharmaceuticals rests on a simple reality: Pharma companies get in trouble all the time. That doesn’t mean they’re bad investments.
By way of explanation, he cited a $390 million settlement Novartis announced over kickback allegations this week. To Ackman, such penalties are just the cost of doing business.
Read Full Article »